Morepen Laboratories Limited — Updates, 29-04-2025: Press Release

Morepen Laboratories has announced a board meeting to discuss the launch of Resmetirom, a new drug targeting non-alcoholic fatty liver disease (NASH). The Bioequivalence study for Resmetirom tablets has received approval, positioning Morepen among the first Indian firms ready for a global launch. With over 115 million people affected by NASH and a rapidly growing market, Morepen's robust regulatory compliance and integrated manufacturing capabilities bolster its potential as an appealing partner and investment in the specialty care sector.